Hurdles for PSE purchases in Louisiana bill
This article was originally published in The Tan Sheet
Buying ephedrine- or pseudoephedrine-containing products in the state becomes more difficult under legislation introduced April 3 by Rep. Fred Mills, a Democrat from the Parks, La., area. House Bill 177 would require pharmacists to ask for photo ID and record the purchase of any methamphetamine precursor for entry into the pharmacy's dispensing information system. Given the "devastating effect" of meth on people in Louisiana, the bill says a pharmacist is best qualified to weigh the benefits of dispensing a precursor product against the risk of illegal use. The Missouri Senate recently rejected a measure that would have made cough/cold products with ephedrine or PSE available by prescription only (1"The Tan Sheet" March 16, 2009, In Brief)
You may also be interested in...
A statewide system for tracking purchases of nonprescription products containing ephedrine or pseudoephedrine is a step closer to reality after the Kansas Senate passes S.B. 248. Following its March 12 approval by 37-3 margin, the bill will next be considered in the state House. Other states have set up similar electronic logbooks to monitor purchases of methamphetamine precursors - including Tennessee, which says its statewide tracking system has been a success (1"The Tan Sheet" Feb. 2, 2009, p. 4). ... Mo. Senate votes down PSE Rx amendment: An attempt to amend a larger crime bill with a measure requiring a prescription for products containing methamphetamine precursors fails in the Missouri state Senate March 4. The amendment offered by state Sen. Jason Crowell, a Republican representing the Cape Girardeau area, "was soundly defeated" by voice vote, according to a legislature spokesman. Separately, Crowell has sponsored a bill, S.B. 160, to make cough/cold remedies containing ephedrine or pseudoephedrine available by prescription only, which remains viable (2"The Tan Sheet" Feb. 23, 2009, p. 3). A companion bill, H.B. 496, is under consideration in the House and has been passed out of committee
EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.